<DOC>
	<DOCNO>NCT01576354</DOCNO>
	<brief_summary>The objective present investigator-initiated mono-center trial perform Department Neurology University Hospital Zurich detail characterization effect prolonged-release fampridine walk function 50-70 patient MS . In randomized , double-blind , placebo-controlled study cross-over design , change essential gait element stability , coordination , correct loading , posture endurance addition walk speed treatment prolonged-release fampridine investigate use comprehensive kinematic gait analysis protocol . This protocol comprise outcome parameter range specific sensitive biomechanical measure clinically meaningful indicator improve ambulatory function . Kinematic , kinetic electromyographic gait parameter assess treadmill walk ( primary outcome parameter ) . Changes overground walk capacity investigate mean different functional walking test ( e.g . six minute walk test ) . Furthermore , patient 's perception effect treatment walk function evaluate standardized questionnaire . Changes global ambulatory activity assess ( Actimeter ) indicate successful translation improve gait ( sub- ) function due prolonged-release fampridine treatment everyday life . The study last period 18 week , exclude screening period . Based mechanism action , investigator hypothesize treatment prolonged-release fampridine improve walk speed , also clinically meaningful feature walk function patient MS. - Trial medicinal product</brief_summary>
	<brief_title>Characterization Effects Prolonged-release Fampridine Ambulatory Function Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Male female subject must 18 65 year old , inclusive , time informed consent . 3 . Must diagnosis either primary progressive , secondary progressive , progressive remitting , relapse remit MS define revise McDonald Committee criterion [ Lublin et al . 1996 ; McDonald et al . 2001 ; Polman et al . 2005 ; Section 22.4 , Appendix L ] least 3 month duration . 4 . Must able walk least 50 meter ( without walk aid ) individual 6minWT conduct prerandomization . 5 . Must impair walk function demonstrate mild gait ataxia ( Functional System ( FS ) score = 2 cerebellar system component EDSS ) FS score &gt; 2 pyramidal system component EDSS base evaluation lower limb ( hip flexor , knee flexor , knee extensor , ankle dorsiflexors ) restrict ambulation ( &lt; 1h walk duration ) Screening Visit . 6 . Female subject childbearing potential must practice effective contraception study willing able continue contraception 30 day last dose study treatment . 7 . Subjects must able understand patient information sheet comply requirement protocol . Main Any history seizure , epilepsy , convulsive disorder , exception febrile seizures childhood . Any prior treatment antiepileptic medication specifically prescribe treatment epilepsy . Onset MS exacerbation within 60 day prior Screening Visit . Use mitoxantrone , cyclophosphamide , rituximab , alemtuzumab , daclizumab , cladribine immune suppressant ( except FTY720 ) antibody ( except natalizumab ) within 3 month prior Screening Visit , schedule use study participation . Pulsed steroid treatment within 60 day prior Screening Visit , time screening period . Women pregnant breast feeding , Clinically significant concomitant disease state renal failure , ( e.g. , moderate severe renal impairment ) , hepatic dysfunction ( e.g. , acute chronic hepatitis ) , cardiovascular pulmonary disease , malignant disease ( tumor , neoplasia ) etc . Participation another study investigational drug within 30 day precede present study . Contraindications class drug study , e.g . know allergy pyridinecontaining substance . Any prior treatment fampridine ( 4aminopyridine ; 4 AP ) 3,4diaminopyridine formulation . Patients acute urinary tract infection Screening Visit indicate symptom like painful urination/dysuria , urinary frequency , urinary urgency , pollakiuria , suprapubic pain , flank pain , costovertebral angle tenderness fever &gt; 38Â°C combination clinically significant pathological finding urine analysis ( e.g. , positive leukocyte ) Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>walk function</keyword>
	<keyword>fampridine</keyword>
</DOC>